Logo Image

Video Shorts

Jacob Stephen Thomas, MD, discusses the use of ipatasertib plus pembrolizumab in head and neck squamous cell carcinoma.
0:37
Highlighting the Efficacy and Safety of Ipatasertib Plus Pembrolizumab in HNSCC
3 months ago
by
Jacob Stephen Thomas, MD
Nicholas Zorko, MD, PhD, University of Minnesota
1:40
Examining the Potential Role of B7-H3 Inhibition in Prostate Cancer
3 months ago
by
Nicholas Zorko, MD, PhD
Sara M. Tolaney, MD, MPH
0:40
Highlighting the Safety Profile of Sacituzumab Govitecan/Pembrolizumab in TNBC
3 months ago
by
Sara M. Tolaney, MD, MPH
Eman E. Ahmed, MB, BCh, Mayo Clinic
0:21
Comparing PSMA PET/CT vs 11C-Choline PET/CT for Disease Progression Monitoring in mCRPC
3 months ago
by
Eman E. Ahmed, MB, BCh
Noa Biran, MD
0:47
Diving into Key Multiple Myeloma Data From ASCO 2026
3 months ago
by
Noa Biran, MD
Priya Rastogi, MD
0:57
Highlighting the Role of MRD Testing in Breast Oncology
3 months ago
by
Priya Rastogi, MD
Ashish Kamat, MD, MD Anderson
0:41
Exploring the Potential Role of Detalimogene Voraplasmid in NMIBC
3 months ago
by
Ashish M. Kamat, MD
Andrew Spencer, MBBS, FRACP, FRCPA, DM
1:05
The Potential of In Vivo CAR T-Cell Therapy in Multiple Myeloma
3 months ago
by
Andrew Spencer, MBBS, FRACP, FRCPA, DM
Adam M. Brufsky, MD, PhD
0:46
Spotlighting the Potential Benefits of the SERENA-6 Trial Design in Breast Cancer
3 months ago
by
Adam M. Brufsky, MD, PhD
Alicia Morgans, MD, Dana-Farber Cancer Institute
1:40
Examining the Cognitive Effects of Darolutamide vs Enzalutamide in Prostate Cancer
3 months ago
by
Alicia Morgans, MD, MPH, FASCO
Jonathan Lee, MD, MSc and Sean Dougherty, MD
0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Manish A. Shah, MD
3 months ago
by
Jonathan Lee, MD, MSc
Bhavana “Tina” Bhatnagar, DO
0:57
The Significance of the phase 3 frontMIND Data in High-Risk DLBCL
3 months ago
by
Bhavana Bhatnagar, DO
Jonathan Lee, MD, MSc and Sean Dougherty, MD
0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Sean Dougherty, MD
3 months ago
by
Jonathan Lee, MD, MSc
Sara M. Tolaney, MD, MPH
0:50
Evaluating the Effect of Response Depth on Treatment Outcomes in DESTINY-Breast09
3 months ago
by
Sara M. Tolaney, MD, MPH
Mabel Mardones, MD
0:49
Assessing Giredestrant-Based Therapy in ER+, HER2-Negative Advanced/Metastatic Breast Cancer
3 months ago
by
Mabel Mardones, MD
ASCO Annual Meeting
3:45
Exploring Notable Posters at the 2026 ASCO Annual Meeting
3 months ago
by
Chinmay Jani, MD
Joaquim Bellmunt, MD, PhD
0:58
What Were the Biggest News at the 2026 ASCO Annual Meeting?
3 months ago
by
Joaquim Bellmunt, MD, PhD
Glenn J. Hanna, MD
0:48
Highlighting the Potential Role of Emi-Le in Aggressive ACC Management
3 months ago
by
Glenn J. Hanna, MD
David Chen, MD, Fox Chase Cancer Center
0:37
Examining the Role of Robotics in Prostate Cancer
3 months ago
by
David Chen, MD
MANEUVER Trial Supports Integration of Targeted Therapy Into Upfront TGCT Management
1:05
Potential Applications for Tumor-Informed ctDNA Deep Sequencing in Osteosarcoma
3 months ago
by
R. Lor Randall, MD, FACS
Virginia G. Kaklamani, MD, DSc
0:39
The Evaluation of HER3-DXd in Breast Cancer
3 months ago
by
Virginia G. Kaklamani, MD, DSc
Geoffrey Ku, MD
1:10
What to Know About Toxicity Management With Zanidatamab Regimens From HERIZON-GEA-01
3 months ago
by
Geoffrey Y. Ku, MD
Fred Saad, MD, Montreal Cancer Institute
1:27
Examining Subgroup Data From PSMAaddition in mHSPC
3 months ago
by
Fred Saad, CQ, MD, FRCS, FCAHS
Mark D. Tyson, II, MD, MPH, Mayo Clinic
1:27
What Were the Most Notable News in Bladder Cancer at AUA 2026?
3 months ago
by
Mark D. Tyson, II, MD, MPH
Joaquim Bellmunt, MD, PhD, Dana-Farber
0:32
Unpacking Patient Reported Outcome Data From IMvigor011 in Bladder Cancer
3 months ago
by
Joaquim Bellmunt, MD, PhD
Geoffrey Ku, MD
1:10
HERIZON-GEA-01 Subgroup Analysis Supports Broad Benefit With Zanidatamab Regimen
3 months ago
by
Geoffrey Y. Ku, MD
Rahul Banerjee, MD, spotlights the phase 3 MonumenTAL-3 trial (NCT05455320) among the key multiple myeloma presentations to watch at the 2026 EHA Congress.
2:32
MonumenTAL-3 Leads Key Myeloma Data Set To Emerge at EHA 2026
3 months ago
by
Rahul Banerjee, MD
Ravi B. Parikh, MD, MPP, FACP, Emory
0:55
What Were Some of the Notable Takeaways From the 2026 ASCO Annual Meeting?
3 months ago
by
Ravi B. Parikh, MD, MPP, FACP
Raj Singh, MD
1:53
Highlighting Brain Cancer Radiation Strategies and Needs for World Brain Tumor Day
3 months ago
by
Raj Singh, MD
Pan-RAS Inhibition Opens New Therapeutic Frontiers in Pancreatic Cancer
1:30
Daraxonrasib Represents a Major Breakthrough for Pancreatic Cancer Care
3 months ago
by
Tanios S. Bekaii-Saab, MD